Adefovir Dipivoxil - CAS 142340-99-6
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
Adefovir Dipivoxil
Catalog Number:
142340-99-6
CAS Number:
142340-99-6
Description:
Adefovir Dipivoxil is a reverse transcriptase inhibitor, used in the treatment of chronic hepatitis B virus (HBV).
Molecular Weight:
501.47
Molecular Formula:
C20H32N5O8P
COA:
Inquire
MSDS:
Inquire
Targets:
HBV
Chemical Structure
CAS 142340-99-6 Adefovir Dipivoxil

Related HBV Products


CAS 209216-23-9 Entecavir Hydrate

Entecavir Hydrate
(CAS: 209216-23-9)

Entecavir-triphosphate is a highly potent inhibitor of wild-type HBV Pol and is 100- to 300-fold more potent than lamivudine-triphosphate against 3TC-resistant ...

CAS 163252-36-6 Clevudine

Clevudine
(CAS: 163252-36-6)

Clevudine is metabolized in cells by the cellular thymidine kinase as well as deoxycytidine kinase to its monophosphate, and subsequently to the di- and triphos...

CAS 203935-39-1 Helioxanthin derivative 5-4-2

Helioxanthin derivative 5-4-2
(CAS: 203935-39-1)

Helioxanthin derivative 5-4-2 had potent anti-HBV activities in HepG2.2.15 cells, with the EC50s of 1 and 0.08 microM, respectively. The lamivudine-resistant HB...

AB-423

AB-423 is a small-molecule inhibitor of HBV core protein used to treat chronic HBV infection. In preclinical study, AB-423 was indicated to damage assembly of t...

CAS 18920-47-3 Helioxanthin

Helioxanthin
(CAS: 18920-47-3)

Helioxanthin and its analogues decreased cellular RNA levels of HBV and antigen expression as well as selective inhibition of HBV replication in a cell culture ...

CAS 840529-13-7 Helioxanthin 8-1

Helioxanthin 8-1
(CAS: 840529-13-7)

Helioxanthin 8-1 is an analogue of helioxanthin, which exhibites significant in vitro anti-HBV/HCV/HSV-1/HIV activity. It showed the most potent antiHBV activi...

CAS 142340-99-6 Adefovir Dipivoxil

Adefovir Dipivoxil
(CAS: 142340-99-6)

Adefovir Dipivoxil is a reverse transcriptase inhibitor, used in the treatment of chronic hepatitis B virus (HBV).

CAS 142217-69-4 Entecavir

Entecavir
(CAS: 142217-69-4)

An oral antiviral drug used in the treatment of hepatitis B infection. A guanine analogue that inhhibits all three steps in the viral replication process.

ABI-H-0731

ABI-H-0731 is one of a class of novel and oral CpAMs developed for the potential use to treat chronic hepatitis B virus infection and disorders associated with ...

CAS 118159-48-1 Bicyclol

Bicyclol
(CAS: 118159-48-1)

Bicyclol is a anti-hepatitis drug, used in China for chronic hepatitis B and presumably C.

CAS 3424-98-4 Telbivudine

Telbivudine
(CAS: 3424-98-4)

Telbivudine is an antiviral drug used in the treatment of hepatitis B infection. It is marketed by Swiss pharmaceutical company Novartis under the trade names S...

CAS 92562-88-4 Lagociclovir

Lagociclovir
(CAS: 92562-88-4)

Lagociclovir is a prodrug of 3'-fluoro-2',3'-dideoxyguanosine with high oral bioavailability in humans and potent activity against HBV.

CAS 198821-22-6 Merimepodib

Merimepodib
(CAS: 198821-22-6)

Merimepodib is orally bioavailable IMPDH inhibitor.

Reference Reading


1.Evolution of entecavir-resistant hepatitis B virus during entecavir and adefovir dipivoxil combination therapy.
Wang Y1, Liu S1, Chen YU1, Zheng S1, Zhou LI1, Hua T2, Sui S2, Lu F3, Duan Z1. Exp Ther Med. 2016 Jan;11(1):117-123. Epub 2015 Nov 12.
The emergence of entecavir (ETV) resistance is rare, particularly in a longitudinal study. The aim of the present study was to characterize the evolution of ETV-resistant variants during antiviral therapy using entecavir monotherapy followed by ETV-adefovir dipivoxil (ADV) combination therapy. The study included a prospective cohort of 53 consecutive chronic hepatitis B (CHB) patients. During the 60-month period of ETV therapy, 2 patients exhibited ETV resistance and their medical records were comprehensively reviewed. A total of 25 consecutive serum samples were regularly collected from the 2 patients. All the samples were used to characterize the evolution of the polymerase gene mutations using pyrosequencing. The linkage of the variants was analyzed from 87 reverse transcriptase sequences of 3 selective samples using clone sequencing. The 2 patients presented with viral breakthrough during ETV monotherapy. In patient A, the rtL180M, rtS202G and rtM204V mutant variants were detected using pyrosequencing prior to virological breakthrough.
2.A hepatitis B- és D-vírus-fertőzés diagnosztikája, antivirális kezelése. Magyar konszenzusajánlás. Érvényes: 2015. szeptember 12-től.
Horváth G1, Gerlei Z2, Gervain J3, Lengyel G4, Makara M5, Pár A6, Rókusz L7, Szalay F3, Tornai I8, Werling K4, Hunyady B6,9. Orv Hetil. 2015 Dec 15;156 Suppl 2:25-36. doi: 10.1556/OH.2015.30331.
Diagnosis and treatment of HBV/HDV infection means for the patient to be able to maintain working capacity, to increase quality of life, to prevent cancer, and to prolong life expectancy, while society benefits from eliminating the chances of further transmission of the viruses, and decreasing the overall costs of serious complications. The guideline delineates the treatment algorithms for 2016 set by a consensus meeting of physicians involved in the treatment of these diseases. The prevalence of HBV infection in the Hungarian general population is 0.5-0.7%. The indications of treatment is based upon viral examinations (including viral nucleic acid determination), determinations of disease activity and stage (including biochemical, pathologic, and/or non-invasive methods), and excluding contraindications. To avoid unnecessary side effects and for cost-effective approach the guideline stresses the importance of quick and detailed virologic evaluations, the applicability of elastography as an acceptable alternative of liver biopsy in this regard, as well as the relevance of appropriate consistent follow up schedule for viral response during therapy.
3.Optimized combination therapies with adefovir dipivoxil (ADV) and lamivudine, telbivudine, or entecavir may be effective for chronic hepatitis B patients with a suboptimal response to ADV monotherap
Li X1, Jie Y1, You X2, Shi H1, Zhang M1, Wu Y1, Lin G1, Li X1, Gao Z1, Chong Y1. Int J Clin Exp Med. 2015 Nov 15;8(11):21062-70. eCollection 2015.
OBJECTIVE: To identify high risk factors in chronic hepatitis B (CHB) patients for suboptimal response to adefovir dipivoxil (ADV) monotherapy, and to assess the efficacy of optimized therapy combining ADV with lamivudine (LAM), telbivudine (LdT), or entecavir (ETV) in patients with a suboptimal response to ADV alone.
4.Cost-effectiveness of Lamivudine, Telbivudine, Adefovir Dipivoxil and Entecavir on decompensated hepatitis B virus-related cirrhosis.
Wang GL1, Liu Y, Qiu P, Zhou SF, Xu LF, Wen P, Wen JB, Xiao XZ. Eur Rev Med Pharmacol Sci. 2016 Mar;20(5):866-72.
OBJECTIVE: To evaluate the cost-effectiveness of lamivudine (LMV), telbivudine (LdT), adefovir dipivoxil (ADV) and entecavir (ETV) on decompensated hepatitis B virus-related cirrhosis.